Oragenics Inc (OGEN)

$1.48 -0.05 (-3.27%)
Market Cap 1.26M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 597,231
Avg Vol 668,596
Day's Range N/A - N/A
Shares Out 823,000.00
Stochastic %K 6%
Beta 0.95
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
NMax
NMax Jul. 7 at 5:21 PM
$OGEN Rocketqueen, 2+ years ago you and I both knew what Oragenics was attempting to do. I asked this board to consider a class-action suit. YOU pressured retail into not taking action. It would seem so that you could take advantage of retail through certain options. Here we are. You're going to be very helpful towards that suit but not as intended
0 · Reply
Rage_monger
Rage_monger Jul. 7 at 4:43 PM
$OGEN
0 · Reply
RocketQueen
RocketQueen Jul. 7 at 4:40 PM
$OGEN know for certain that Oragenics is currently being investigated by multiple law firms for breach of fiduciary as well as scienter fraud.. I would encourage folks to keep filing complaints with law firms, the SEC, Florida AG and FINRA as it takes time an patience to get a bite. Oragenics lives and breathes off corporate loopholes and so we need to flood the space with the truth about what's going on here.
0 · Reply
Rage_monger
Rage_monger Jul. 7 at 4:23 PM
$OGEN 100% JANET HUFFMAN.
0 · Reply
NMax
NMax Jul. 7 at 4:19 PM
$OGEN shorts (like Racketqueen) assisted in the artificial devaluation of this asset thinking they would in return receive favorable dilution before the acquisition completed. Perhaps they got dooped? And they arent too happy about it.
0 · Reply
NMax
NMax Jul. 7 at 4:12 PM
$OGEN Institutional holdings are low because... in preparation of a buyout they took park in private placements to hide accumulation. Specifically of preferred shares which liquidate first.
0 · Reply
NMax
NMax Jul. 7 at 3:58 PM
$OGEN Hey Racketqueen. Remember 2 + years ago. (Probably around the time I blocked you) I mentioned on this board shareholders should be looking into a class action. Do you remember posting on this board that we shouldn't be talking about a class-action?? Instead! You wait until right around acquisition time when shorts are looking f'd to start talking about a suit? Not suspicious at all.
0 · Reply
NMax
NMax Jul. 7 at 3:49 PM
$OGEN "planning" Sure thing bud. Sure thing...🙄
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 7 at 3:49 PM
$OGEN wow, shorts be prepared to get burned hard!!
0 · Reply
sincosine
sincosine Jul. 7 at 3:45 PM
$OGEN great stock wow .
0 · Reply
Latest News on OGEN
Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 4 days ago

Oragenics Completes Approximately $16.5 Million Offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 6 days ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 7 weeks ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 2 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 3 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 3 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 3 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 4 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 4 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 5 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 5 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 5 months ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 7 months ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 9 months ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 9 months ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 9 months ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 10 months ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 10 months ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 11 months ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 11 months ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 11 months ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 11 months ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 11 months ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 1 year ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 1 year ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 1 year ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 1 year ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 1 year ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 1 year ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 1 year ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 1 year ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 1 year ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Sep 29, 2023, 4:00 PM EDT - 1 year ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Oragenics, Inc. Announces Private Placement

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Private Placement

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Jun 5, 2023, 4:18 PM EDT - 2 years ago

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Oragenics to Participate in the World Vaccine Congress Washington

Mar 29, 2023, 11:45 AM EDT - 2 years ago

Oragenics to Participate in the World Vaccine Congress Washington

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Mar 14, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Mar 8, 2023, 9:09 AM EST - 2 years ago

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Mar 1, 2023, 7:30 AM EST - 2 years ago

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

NMax
NMax Jul. 7 at 5:21 PM
$OGEN Rocketqueen, 2+ years ago you and I both knew what Oragenics was attempting to do. I asked this board to consider a class-action suit. YOU pressured retail into not taking action. It would seem so that you could take advantage of retail through certain options. Here we are. You're going to be very helpful towards that suit but not as intended
0 · Reply
Rage_monger
Rage_monger Jul. 7 at 4:43 PM
$OGEN
0 · Reply
RocketQueen
RocketQueen Jul. 7 at 4:40 PM
$OGEN know for certain that Oragenics is currently being investigated by multiple law firms for breach of fiduciary as well as scienter fraud.. I would encourage folks to keep filing complaints with law firms, the SEC, Florida AG and FINRA as it takes time an patience to get a bite. Oragenics lives and breathes off corporate loopholes and so we need to flood the space with the truth about what's going on here.
0 · Reply
Rage_monger
Rage_monger Jul. 7 at 4:23 PM
$OGEN 100% JANET HUFFMAN.
0 · Reply
NMax
NMax Jul. 7 at 4:19 PM
$OGEN shorts (like Racketqueen) assisted in the artificial devaluation of this asset thinking they would in return receive favorable dilution before the acquisition completed. Perhaps they got dooped? And they arent too happy about it.
0 · Reply
NMax
NMax Jul. 7 at 4:12 PM
$OGEN Institutional holdings are low because... in preparation of a buyout they took park in private placements to hide accumulation. Specifically of preferred shares which liquidate first.
0 · Reply
NMax
NMax Jul. 7 at 3:58 PM
$OGEN Hey Racketqueen. Remember 2 + years ago. (Probably around the time I blocked you) I mentioned on this board shareholders should be looking into a class action. Do you remember posting on this board that we shouldn't be talking about a class-action?? Instead! You wait until right around acquisition time when shorts are looking f'd to start talking about a suit? Not suspicious at all.
0 · Reply
NMax
NMax Jul. 7 at 3:49 PM
$OGEN "planning" Sure thing bud. Sure thing...🙄
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 7 at 3:49 PM
$OGEN wow, shorts be prepared to get burned hard!!
0 · Reply
sincosine
sincosine Jul. 7 at 3:45 PM
$OGEN great stock wow .
0 · Reply
pelkie85
pelkie85 Jul. 7 at 3:45 PM
$OGEN where's the pumpers now ???
0 · Reply
RocketQueen
RocketQueen Jul. 7 at 3:29 PM
$OGEN @Nmax actually do plan to contact the NYSE mkt to question their reasoning or basis for allowing a company like Oragenics to remain on a national listing. OGEN is now 5x below the minimum compliance level and should get immediately booted out with no questions asked.
0 · Reply
WolfOfQv
WolfOfQv Jul. 7 at 3:26 PM
$OGEN damn how much u lost
1 · Reply
NMax
NMax Jul. 7 at 3:12 PM
$OGEN Racketqueen, you spend months posting here, obsessing over someone that blocked you years ago. Posting constantly every day on a stock you hate and have no shares in. Does that make sense to you? If you were legit, you'd be hammering out your bs lawsuit. But your short. Yout in a bind. Facing a pre-aquisition squeeze in slow motion. You're in a worse position than anyone here and theres nothing you can do but the same old thing. And it just doesn't work.
1 · Reply
RocketQueen
RocketQueen Jul. 7 at 3:00 PM
$OGEN @Nmax should be jailed for his talk about a buyout. This company has no products, no services, no employees, no offices and no labs. What would a buyer get from Oragenics other than a briefcase full of fraudulent biotech scam ideas? Cue Crickets....
1 · Reply
NMax
NMax Jul. 7 at 2:52 PM
$OGEN They've known about this acquisition for years. Preferred shares take priority over common shares during an acquisition. Again this was play to remove as much value from retail as possible. Shorts are clearly in a bind though. These preferred shares likely won't be converted. And will be held for the deal to be completed.
0 · Reply
profitingstocks
profitingstocks Jul. 7 at 2:50 PM
$OGEN So Janet has made approx $165K in salary for the past 6 months since she became CEO, plus a $75K bonus for taking the role. Meanwhile under her “leadership” the stock price has lost 90% of its value. Truly amazing work, how do you fuck up this badly and still get a decent wage?
1 · Reply
SXCross
SXCross Jul. 7 at 2:45 PM
$OGEN My holdings of OGEN have doubled - thanks to the short sellers.
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 7 at 2:27 PM
$OGEN sell for a loss everyday...yeah, thats the way dummies... I'm holding..gfy
2 · Reply
subxero55
subxero55 Jul. 7 at 2:03 PM
$OGEN out.. never listen to pumpers always buy ur own shyt... i wont make this mistake again
0 · Reply
mi_ama_llama
mi_ama_llama Jul. 7 at 2:00 PM
$OGEN gonna have to report this one to the sec for manipulation
0 · Reply
subxero55
subxero55 Jul. 7 at 1:51 PM
$OGEN 1.45 bid lmao ya fukin pests
0 · Reply